{"id":497392,"date":"2020-07-21T12:58:01","date_gmt":"2020-07-21T12:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=497392"},"modified":"2020-07-21T12:58:01","modified_gmt":"2020-07-21T12:58:01","slug":"primary-immunodeficiency-disease-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/primary-immunodeficiency-disease-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_497392.html","title":{"rendered":"Primary Immunodeficiency Disease Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Primary Immunodeficiency Disease Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Primary Immunodeficiency Disease Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Primary Immunodeficiency Disease (PIDD) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight has launched a new report on &ldquo;<strong>Primary Immunodeficiency Disease (PIDD) &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/strong>&rdquo;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/primary-immune-deficiency-pid-market\">Primary Immunodeficiency Disease Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/strong><strong>&#8220;<\/strong>&nbsp;report delivers an in-depth understanding of the Primary Immunodeficiency Disease (PID), historical and forecasted epidemiology as well as the Primary Immunodeficiency Disease (PID) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of the Report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>According to Delveinsight&rsquo;s Analysts, more than 200 different forms of Primary Immunodeficiency Diseases affecting approximately 500,000 people in the United States and these rare genetic diseases may be debilitating, chronic, and costly.<\/li>\n<li>According to Delveinsight&rsquo;s estimates, severe combined immunodeficiency (SCID) is a rare genetic disorder, affecting one in 30,000 new borns.<\/li>\n<li>The Market size of PIDD is expected to increase for the study period of 2017-2030.<\/li>\n<li>According to Delveinsight, Primary Immunodeficiency Disease Market is expected to grow at a CAGR of XX%.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Report Key Highlights:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li><strong>Primary Immunodeficiency Disease <\/strong>market report covers a descriptive overview and comprehensive insight of the PIDD epidemiology and&nbsp;<strong>Primary Immunodeficiency Disease <\/strong>market in the 7 MM (United States, EU5 (Germany,&nbsp;Spain,&nbsp;France,&nbsp;Italy, UK) &amp;&nbsp;Japan.)<\/li>\n<li><strong>Primary Immunodeficiency Disease <\/strong>market report provides the insights on the current and emerging&nbsp;<em>PIDD<\/em>&nbsp;therapies.<\/li>\n<li><strong>Primary Immunodeficiency Disease <\/strong>market report provides global historical and forecasted market covering drug outreach in 7 MM.<\/li>\n<li><strong>Primary Immunodeficiency Disease <\/strong>market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the <strong>Primary Immunodeficiency Disease <\/strong>market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/primary-immune-deficiency-pid-market\">https:\/\/www.delveinsight.com\/sample-request\/primary-immune-deficiency-pid-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/primary-immune-deficiency-pid-market\">Primary immunodeficiency disease (PIDD)<\/a><\/strong> is a condition in which the immune system is weaker than normal. The term &#8220;primary&#8221; implies that there is an independent problem of the immune system rather than a weakening of the immune system due to another condition like&nbsp;<strong>HIV\/AIDS<\/strong>&nbsp;(a secondary immune deficiency).<\/p>\n<p style=\"text-align: justify;\">Primary immunodeficiency disease is most often identified in infants and children, but it is possible that the condition is identified in adulthood. Primary immunodeficiency disease represents a diverse group of hundreds of diseases that can weaken the immune system.<\/p>\n<p style=\"text-align: justify;\">Most often, primary immunodeficiency disease results in increased susceptibility to both acute and chronic (long-term) infections.<\/p>\n<p style=\"text-align: justify;\">The types of primary immunodeficiency disease are far too numerous to list here. Examples of some of the more commonly known primary immunodeficiency diseases include:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Wiscott-Aldrich syndrome<\/li>\n<li>Severe combined immunodeficiency disease (SCID)<\/li>\n<li>DiGeorge syndrome<\/li>\n<li><strong>Ataxia-telangectasia<\/strong><\/li>\n<li>Chronic granulomatous disease<\/li>\n<li>Transient hypogammaglobulinemia of infancy<\/li>\n<li>Agammaglobulinemia<\/li>\n<li>Complement deficiencies<\/li>\n<li>Selective IgA deficiency<\/li>\n<li>And Many More<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/69f484b2efe2ba90924094e6bd9bb345.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/primary-immune-deficiency-pid-market\">https:\/\/www.delveinsight.com\/sample-request\/primary-immune-deficiency-pid-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies involved:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Octapharma<\/li>\n<li>Takeda<\/li>\n<li>X4 Pharmaceuticals<\/li>\n<li>Kedrion<\/li>\n<li>CSL Behring<\/li>\n<li>Grifols<\/li>\n<li>Pfizer<\/li>\n<li>Shire<\/li>\n<li>And Many More<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Drugs:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Cutaquig<\/li>\n<li>HyQvia<\/li>\n<li>X4P-001<\/li>\n<li>10%IVIG<\/li>\n<li>PRIVIGEN<\/li>\n<li>GAMUNEX<sup>&reg;<\/sup>-C<\/li>\n<li>And Many More<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/primary-immune-deficiency-pid-market\">https:\/\/www.delveinsight.com\/sample-request\/primary-immune-deficiency-pid-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Primary Immunodeficiency Disease (PIDD)<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Primary Immunodeficiency Disease (PIDD)<\/p>\n<p style=\"text-align: justify;\">4. Primary Immunodeficiency Disease (PIDD): Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Primary Immunodeficiency Disease (PIDD): Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Primary Immunodeficiency Disease (PIDD) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Primary Immunodeficiency Disease (PIDD) Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Primary Immunodeficiency Disease (PIDD): Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Primary Immunodeficiency Disease (PIDD)<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/primary-immune-deficiency-pid-market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Primary Immunodeficiency Disease (PIDD) &#8211; Epidemiology Forecast to 2030<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;<strong>Primary Immunodeficiency Disease (PIDD) &#8211; Epidemiology Forecast to 2030<\/strong>&#8216; report delivers an in-depth understanding of the disease, historical and forecasted Primary Immunodeficiency Disease (PIDD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Primary Immunodeficiency Disease (PIDD) &#8211; Pipeline Insights, 2020<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;<strong>Primary Immunodeficiency Disease (PIDD) Pipeline Insight, 2020<\/strong>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Primary Immunodeficiency Disease (PIDD)&nbsp;<\/strong>market.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=primary-immunodeficiency-disease-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-immune-deficiency-pid-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/primary-immune-deficiency-pid-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/primary-immune-deficiency-pid-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=primary-immunodeficiency-disease-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Primary Immunodeficiency Disease (PIDD) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; DelveInsight has launched a new report on &ldquo;Primary Immunodeficiency Disease (PIDD) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&rdquo; &nbsp; DelveInsight&#8217;s &#8220;Primary Immunodeficiency Disease Market Insights, Epidemiology, and Market Forecast-2030&#8220;&nbsp;report &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/primary-immunodeficiency-disease-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_497392.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-497392","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=497392"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497392\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=497392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=497392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=497392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}